

For the acute treatment of migraine and the preventive treatment of episodic migraine in adults

NURTEC ODT DOSAGE GUIDE

Nurtec[®] ODT
(rimegepant)
orally disintegrating tablets 75 mg

TREATING MIGRAINE ATTACKS¹

Prescribe 8 or 16 tablets.

SIG: Take one Nurtec ODT 75 mg, **as needed**, for the acute treatment of migraine with or without aura.¹

PREVENTING MIGRAINE ATTACKS¹


Prescribe 16 tablets.

SIG: Take one Nurtec ODT 75 mg **every other day** for the preventive treatment of episodic migraine.¹

Additional considerations:

- A non-CGRP acute treatment can be used on days when Nurtec ODT is taken, if needed.²
- The safety of using more than 18 doses in a 30-day period has not been established.¹

CGRP=calcitonin gene-related peptide



For more information, visit
nurtec-hcp.com/dosing-administration

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Please see full Important Safety Information on the next page and click here for full Prescribing Information.

INDICATIONS:

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please click here for full [Prescribing Information](#).

References: **1.** Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. **2.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7

© 2023 Pfizer Inc. All rights reserved.

NURTEC and the NURTEC Logo are trademarks of Pfizer Ireland Pharmaceuticals.

March 2023. PP-NNT-USA-0260.

